{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:26:39Z","timestamp":1781191599392,"version":"3.54.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["200622"],"award-info":[{"award-number":["200622"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Current standard-of-care treatments for hypereosinophilic syndrome (HES) include oral corticosteroids (OCS) and immunosuppressive\/cytotoxic (IS\/CT) therapies. The anti-IL-5 monoclonal antibody mepolizumab has also recently been approved for patients with this disease. The objective of this analysis was to assess the relationship between baseline therapy and flare reduction in patients with HES treated with mepolizumab, using data from the Phase III 200622 study (NCT02836496).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In the double-blind, parallel-group 200622 study, eligible patients were \u226512 years old and had HES for \u22656 months, \u22652 flares in the previous 12 months, blood eosinophils \u22651000 cells\/\u03bcL at screening and \u22654 weeks\u2019 stable HES therapy. Patients were randomised (1:1) to receive mepolizumab 300 mg subcutaneously or placebo every 4 weeks for 32 weeks plus their existing HES therapy. This <jats:italic>post hoc<\/jats:italic>, descriptive analysis assessed the effect of baseline HES therapy [IS\/CT (\u00b1 OCS), OCS No IS\/CT, and No IS\/CT\/OCS] on the proportion of patients with \u22651 flare during the study period, the annualised rate of flares, time to first flare, and the proportion of patients with \u22651 flare during Weeks 20\u250032, with mepolizumab versus placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mepolizumab treatment was associated with a decrease in the proportion of patients who experienced \u22651 flare during the study period in all baseline therapy groups versus placebo (32\u201396% reduction). Similarly, the probability of a flare was lower with mepolizumab (14.3\u201331.4%) than placebo (35.7\u201374.1%) in all baseline therapy groups, as was the annualised flare rate (0.22\u20130.68 vs 1.14\u20131.62). The proportion of patients who experienced \u22651 flare during Weeks 20\u201332 was reduced with mepolizumab versus placebo for all baseline therapy groups (55\u201385% reduction). For all endpoints, the greatest effect of mepolizumab treatment was seen in the IS\/CT (\u00b1 OCS) group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients with poorly controlled HES are likely to achieve clinical benefit with mepolizumab in terms of flare reduction, regardless of their baseline therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p>(<jats:uri>https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02836496<\/jats:uri>).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.840974","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T13:14:27Z","timestamp":1649855667000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Andreas","family":"Reiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namhee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Mavropolou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Yancey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Steinfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8506-7","article-title":"Hypereosinophilic Syndrome","volume":"50","author":"Curtis","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic Syndrome: A Multicenter, Retrospective Analysis of Clinical Characteristics and Response to Therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00216","article-title":"(A Critical Appraisal of) Classification of Hypereosinophilic Disorders","volume":"4","author":"Kahn","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2007.07.001","article-title":"Cardiovascular Manifestations of Hypereosinophilic Syndromes","volume":"27","author":"Ogbogu","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s13601-019-0277-4","article-title":"Eosinophilic Disorders: Evaluation of Current Classification and Diagnostic Criteria, Proposal of a Practical Diagnostic Algorithm","volume":"9","author":"Leru","year":"2019","journal-title":"Clin Trans Allergy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26352","article-title":"World Health Organization-Defined Eosinophilic Disorders: 2021 Update on Diagnosis, Risk Stratification, and Management","volume":"97","author":"Shomali","year":"2021","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00049","article-title":"Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other Than Asthma","volume":"5","author":"Roufosse","year":"2018","journal-title":"Front Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-pathmechdis-012419-032756","article-title":"Contributions of Eosinophils to Human Health and Disease","volume":"15","author":"Klion","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: A Phase III, Randomized, Placebo-Controlled Trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B10","unstructured":"EMAMepolizumab (NUCALA) Summary of Product Characteristics2021"},{"key":"B11","unstructured":"GSKMepolizumab (NUCALA) Highlights of Prescribing Information2021"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10787-010-0056-2","article-title":"Anti-Inflammatory Glucocorticoid Drugs: Reflections After 60 Years","volume":"19","author":"Whitehouse","year":"2011","journal-title":"Inflammopharmacology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I Treat Hypereosinophilic Syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14488","article-title":"Guideline for the Investigation and Management of Eosinophilia","volume":"176","author":"Butt","year":"2017","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.326","article-title":"Hypereosinophilic Syndrome: Approach to Treatment in the Era of Precision Medicine","volume":"2018","author":"Klion","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/all.12843","article-title":"Clinical Features Predict Responsiveness to Imatinib in Platelet-Derived Growth Factor Receptor-Alpha-Negative Hypereosinophilic Syndrome","volume":"71","author":"Khoury","year":"2016","journal-title":"Allergy"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or Placebo for Eosinophilic Granulomatosis With Polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/jaa.s275944","article-title":"Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma","volume":"13","author":"Silver","year":"2020","journal-title":"J Asthma Allergy"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of Patients With the Hypereosinophilic Syndrome With Mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"New Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study","volume":"9","author":"Gleich","year":"2021","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.840974\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T13:14:29Z","timestamp":1649855669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.840974\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2022.840974"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.840974","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,13]]},"article-number":"840974"}}